



(51) International Patent Classification:  
Not classified

(21) International Application Number:  
PCT/PT2018/050035

(22) International Filing Date:  
14 September 2018 (14.09.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
1715008.7 18 September 2017 (18.09.2017) GB

(71) Applicant: **INSTITUTO DE MEDICINA MOLECULAR** [PT/PT]; Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 1649-028 Lisbon (PT).

(72) Inventors: **BERNARDES, Gonçalo**; Instituto de Medicina Molecular, Av. Prof. Egas Moniz, 1649-028 Lisbon (PT). **RODRIGUES, Tiago**; Instituto de Medicina Molecular, Av. Prof. Egas Moniz, 1649-028 Lisbon (PT). **CONDE, João**; Instituto de Medicina Molecular, Av. Prof. Egas Mo-

niz, Lisbon (PT). **BAKER, Charlotte**; Instituto de Medicina Molecular, Av. Prof. Egas Moniz, 1649-028 Lisbon (PT).

(74) Agent: **STILWELL D'ANDRADE, Vasco**; Rua Castilho, 165, 1070-050 Lisbon (PT).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: TRPV2 ANTAGONISTS




Figure 1A

(57) Abstract: This invention relates to the finding that Piperlongumine compounds, such as Piperlongumine and analogues, derivatives and prodrugs thereof, are reversible, allosteric antagonists of transient receptor potential vanilloid 2 channel (TRPV2). Methods of treatment of conditions that are characterised by TRPV2 expression using Piperlongumine compounds and Piperlongumine compounds for use in such treatments are provided

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— *of inventorship (Rule 4.17(iv))*

**Published:**

— *without international search report and to be republished  
upon receipt of that report (Rule 48.2(g))*